[EN] [1,2,4] TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES [FR] DÉRIVÉS DE [1,2,4] TRIAZOLO UTILISÉS EN TANT QU'INHIBITEURS DE PDE1 POUR LE TRAITEMENT DU DIABÈTE
[EN] [1,2,4] TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES [FR] DÉRIVÉS DE [1,2,4] TRIAZOLO UTILISÉS EN TANT QU'INHIBITEURS DE PDE1 POUR LE TRAITEMENT DU DIABÈTE
[1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES
申请人:Eli Lilly and Company
公开号:EP3665174A1
公开(公告)日:2020-06-17
[EN] [1,2,4] TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] DÉRIVÉS DE [1,2,4] TRIAZOLO UTILISÉS EN TANT QU'INHIBITEURS DE PDE1 POUR LE TRAITEMENT DU DIABÈTE
申请人:LILLY CO ELI
公开号:WO2019032383A1
公开(公告)日:2019-02-14
The present invention provides a compound of Formula I: wherein X is CH2CH2, CH2CH2CH2, OCH2, or CH2O; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CH2CH2, then R is other than cyclopropyl; for use as a human PDE1 inhibitor.